Vivo Bio Tech balance sheet

As of Mar 2025

Total assets: ₹141cr+4.8% on Mar 2024
Shareholders' equity: ₹78.2cr+43.7% on Mar 2024
Total debt: ₹51.8cr−26.9% on Mar 2024
Cash and investments: ₹1.2cr−8.1% on Mar 2024

₹ crore except per share

Tap a line for its trend	FY25Mar 2025	FY24Mar 2024

Non-current assets
	61.0	68.9
	12.8	9.2
	23.9	8.1
	0.0	0.0
	0.0	0.0
	0.2	0.3
	98.0	86.6
Current assets
	7.8	8.8
	11.2	11.4
	1.2	1.3
	22.3	25.7
	34.8	38.4
	0.8	1.1
	43.3	48.2
	141	135
Equity
	17.2	14.9
	61.0	39.5
	78.2	54.4
	78.2	54.4
Liabilities
	32.7	39.6
	32.7	39.6
	1.8	2.3
	0.8	0.7
	35.3	42.6
	19.1	31.3
	1.0	1.1
	20.1	32.3
	7.8	5.5
	27.8	37.8
	63.1	80.4
	141	135

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

VIVOBIOT₹13.98

Vivo Bio Tech Limited

· Pharma & Health

₹ CroreMcap ₹21.4 Cr

View

In ₹ Crore except Per Share As of	FY24 31/03/2024	FY25 31/03/2025
Non-current Assets
+ Property, Plant & Equipment	68.9	61.0
+ Capital Work-in-Progress	9.2	12.8
+ Other Intangibles	8.1	23.9
+ Non-current Investments	0.0	0.0
Non-current Financial Assets	0.0	0.0
+ Other Non-current Assets	0.3	0.2
Total Non-current Assets	86.6	98.0
Current Assets
+ Inventories	8.8	7.8
+ Trade Receivables	11.4	11.2
+ Cash & Cash Equivalents	1.3	1.2
+ Short-term Loans	25.7	22.3
Current Financial Assets	38.4	34.8
+ Other Current Assets	1.1	0.8
Total Current Assets	48.2	43.3
Total Assets	134.8	141.3
Equity
+ Equity Share Capital	14.9	17.2
+ Other Equity / Reserves	39.5	61.0
Equity — Owners of Parent	54.4	78.2
Total Equity	54.4	78.2
Liabilities
+ Borrowings — Non-current	39.6	32.7
Non-current Financial Liabilities	39.6	32.7
+ Deferred Tax Liabilities	2.3	1.8
+ Other Non-current Liabilities	0.7	0.8
Non-current Liabilities	42.6	35.3
+ Borrowings — Current	31.3	19.1
+ Trade Payables	1.1	1.0
Current Financial Liabilities	32.3	20.1
+ Provisions — Current	5.5	7.8
Current Liabilities	37.8	27.8
Total Liabilities	80.4	63.1
Total Equity & Liabilities	134.8	141.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.